Vivoryon Therapeutics N.V./€VVY
1D1W1MYTD1Y5YMAX
Capital at risk
About Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. is a clinical-stage biotechnology company specializing in the development of small molecule medicines targeting post-translational modifications implicated in various diseases. Its lead candidate, varoglutamstat, is an oral inhibitor of glutaminyl cyclases (QPCT and QPCTL) with potential applications in inflammatory and fibrotic diseases, neurodegenerative conditions, and cancer. Originally focused on Alzheimer's disease, the company shifted its strategic emphasis to kidney diseases in 2024 after observing significant improvements in kidney function during clinical trials. Headquartered in Halle (Saale) and Munich, Germany, Vivoryon has expanded its intellectual property portfolio, including a U.S. patent granted in May 2025 for varoglutamstat, providing exclusivity through 2044. The company's unique approach centers on modulating disease-related protein activity and stability through targeted enzyme inhibition.
- Ticker
- €VVY
- Sector
- Health
- Primary listing
- AEX
- Employees
- 13
- Headquarters
- Halle, Germany
- Website
- www.vivoryon.com
VVY Metrics
BasicAdvanced
€33M
-
-€0.24
1.45
-
Price and volume
Market cap
€33M
Beta
1.45
52-week high
€1.87
52-week low
€0.96
Average daily volume
30K
Financial strength
Current ratio
4.561
Quick ratio
4.025
Long term debt to equity
0.007
Total debt to equity
0.049
Interest coverage (TTM)
-157.67%
Profitability
EBITDA (TTM)
-6.733
Management effectiveness
Return on assets (TTM)
-80.06%
Return on equity (TTM)
-285.21%
Valuation
Price to book
20.82
Price to tangible book (TTM)
40.72
Price to free cash flow (TTM)
-4.534
Free cash flow yield (TTM)
-22.06%
Free cash flow per share (TTM)
-0.247
Growth
Earnings per share change (TTM)
-50.80%
3-year earnings per share growth (CAGR)
-39.72%
10-year earnings per share growth (CAGR)
-18.61%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.